Drug Trial Radar · NCT07586306
A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jul 31, 2027
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centre, single- arm, non-randomized, open-label phase 1/2 clinical trial which enables dosing of the fellow eyes of patients who received VGR-R01 administration in previous studies.
Conditions
- Bietti Crystalline Dystrophy
Interventions
VGR-R01Biological
CYP4v2-coding gene delivered by AAV vector
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and serious adverse eventsTime frame: Up to Year 5
- Number of participants with clinically significant change from baseline in vital signs, clinically laboratory abnormalities and ophthalmic examination findingsTime frame: Up to Year 5
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
Shanghai General Hospital (Shanghai First People's Hospital)
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.